Blog Exposure – Karyopharm Inked Deal with Antengene for Development and Commercialization of Selinexor, Eltanexor, Verdinexor, and KPT-9274 in Asia

Stock Monitor: PetIQ Post Earnings Reporting

LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want access to our free research report on Karyopharm Therapeutics Inc. (NASDAQ: KPTI), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KPTI as the Company’s latest news hit the wire. On May 24, 2018, the Company announced that it has signed an exclusive license agreement with Antengene Corp. for the development and commercialization of four of Karyopharm’s novel, oral drug candidates, including selinexor, eltanexor, verdinexor, and KPT-9274. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for PetIQ, Inc. (NASDAQ: PETQ), which also belongs to the Healthcare sector as the Company Karyopharm Therapeutics. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=PETQ

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Karyopharm Therapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=KPTI

The agreement includes the development and commercialization of selinexor and eltanexor for the diagnosis, treatment, and prevention of all human oncology indications in China and Macau. The agreement also includes the development and commercialization of KPT-9274 in all human oncology indications and verdinexor in human non-oncology indications in mainland China, Macau, Taiwan, Hong Kong, South Korea, and the ASEAN countries.

Terms of the Agreement

Karyopharm will receive a one-time upfront payment of $12 million from Antengene. Karyopharm is eligible to receive up to an additional $150 million if certain future pre-specified development, regulatory, and commercial milestones are achieved by Antengene.

Karyopharm is also eligible to receive tiered double-digit royalties based on future net sales of selinexor and eltanexor in China and Macau, and tiered single- to double-digit royalties based on future net sales of verdinexor and KPT-9274 in the relevant territories.

In exchange, Antengene will receive exclusive rights to develop, manufacture, and commercialize the compounds in the agreed to territories, at its own cost and expense.

Antengene will have the ability to participate in any global clinical study of selinexor, eltanexor, verdinexor, or KPT-9274, and it will bear the cost and expense for patients enrolled in clinical studies in the agreed to territories.

Antengene may Initiate Additional Clinical Trials in Diseases with High Incidence in Greater China and other Asian Regions

Jay Mei, MD, PhD, Chairman and CEO of Antengene, stated that this agreement with Karyopharm brings to Antengene’s pipeline four promising, clinical-stage product candidates with broad applicability across multiple disease areas, with a particular focus in oncology, with the potential to help patients in a number of Asian territories.

Jay added that to complement the ongoing clinical development efforts by Karyopharm, Antengene may initiate additional clinical trials in diseases with high incidence in Greater China and other Asian regions.

Collaboration Complements Karyopharm’s Existing Partnership with Ono Pharma for Selinexor and Eltanexor in Asia

Michael G. Kauffman, MD, PhD, CEO of Karyopharm, mentioned that this strategic alliance adds to the impressive consortium of global Karyopharm’s partners who are actively advancing the Company’s novel oral drug candidates in these important markets, while allowing it to focus its internal resources on executing the late-phase selinexor trials and pursue regulatory approval in the United States and the European Union.

Michael added that in particular, this collaboration for additional territories in Asia complements Karyopharm’s existing partnership with Ono Pharmaceutical for selinexor and eltanexor in Japan, Taiwan, South Korea, Hong Kong, and the ASEAN countries.

About Selinexor, Eltanexor, Verdinexor, and KPT-9274

Selinexor (KPT-330) is a first in class SINE XPO1 antagonist, being evaluated in multiple Phase-2/3 clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. Selinexor has been granted Orphan Drug Designation in multiple myeloma and Fast Track designation for the patient population evaluated in the STORM study.

Eltanexor (KPT-8602) is a second generation oral SINE compound. Eltanexor functions by binding to and inhibiting the nuclear export protein XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. A Phase-1/2 clinical study is currently ongoing evaluating eltanexor in myelodysplastic syndrome, colorectal cancer and castrate-resistant prostate cancer.

Verdinexor (KPT-335) is in development for the treatment of viral indications. Several viruses exclusively utilize XPO1 to shuttle cargos necessary for virion assembly such as viral ribonucleoproteins, or vRNA, and proteins from the nucleus to the cytoplasm. Verdinexor has the potential to treat viral diseases through both inhibition of viral replication and suppression of inflammatory cytokine-mediated symptoms and shows significant anti-influenza activity in murine and ferret models.

KPT-9274 is a first-in-class, orally bioavailable, small molecule immunometabolic modulator that works through non-competitive dual inhibition of p21-activated kinase 4 (PAK4) and NAMPT. NAMPT and NAPRT are the two main pathways for production of the NAD (nicotinamide dinucleotide). About 15%-30% of all solid tumors are deficient in NAPRT, making them reliant on NAMPT for NAD production. Tumors deficient in NAPRT may be particularly susceptible to KPT-9274’s actions. KPT-9274 is currently being evaluated in a Phase-1 clinical study in advanced solid tumors and non-Hodgkin’s lymphoma.

About Karyopharm Therapeutics Inc.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm Therapeutics is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.

About Antengene Corp.

Founded in 2016, Antengene is a clinical-stage biopharmaceutical company that focuses on introducing cutting-edge treatments, ranging from early-to-late stage development pipelines to mature brands, to China and other Asian markets. The Company is based in Shanghai, China.

Stock Performance Snapshot

May 25, 2018 – At Friday’s closing bell, Karyopharm Therapeutics’ stock advanced 1.96%, ending the trading session at $17.68.

Volume traded for the day: 668.64 thousand shares.

Stock performance in the last month – up 18.74%; previous three-month period – up 18.98%; past twelve-month period – up 94.50%; and year-to-date – up 84.17%

After last Friday’s close, Karyopharm Therapeutics’ market cap was at $1.02 billion.

The stock is part of the Healthcare sector, categorized under the Drugs – Generic industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visithttp://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 501036